Marzelle J, Combe S, Gigou F, Samama M
Service de Chirurgie thoracique et vasculaire, Hôpital Marie-Lannelongue, Le Plessis-Robinson.
J Mal Vasc. 1988;13(4):307-16.
After describing the mechanism of action, results and local and general complications of classical thrombolytic agents (streptokinase and urokinase) administered systemically, locally and peroperatively, then of modern thrombolytic agents (acyl enzyme, tPA and scuPA), the future perspectives of arterial fibrinolysis are discussed. These are based upon: analysis of the comparative efficacy of the different thrombolytic agents in the light of results seen, not only in peripheral arterial pathology but also in other indications, as in coronary pathology; discussion of the methods of administration of the thrombolytic agent in such a way as to obtain an optimal local concentration and at the same time reduced systemic fibrinolysis. better definition of the indications of thrombolysis in acute ischemia of the limbs in comparison with other therapeutic approaches, in particular surgery, taking into account the degree of ischemia, of etiological mechanism and the site of the arterial obstruction.
在描述了经典溶栓剂（链激酶和尿激酶）全身、局部及术中给药的作用机制、结果以及局部和全身并发症，接着描述了现代溶栓剂（酰化酶、组织型纤溶酶原激活剂和单链尿激酶型纤溶酶原激活剂）的相关情况后，讨论了动脉内纤维蛋白溶解的未来前景。这些前景基于以下方面：根据所观察到的结果，不仅分析不同溶栓剂在外周动脉疾病中的疗效比较，还分析其在其他适应症（如冠状动脉疾病）中的疗效；讨论溶栓剂的给药方法，以便获得最佳局部浓度，同时减少全身纤维蛋白溶解；与其他治疗方法（特别是手术）相比，根据肢体急性缺血的缺血程度、病因机制和动脉阻塞部位，更好地界定溶栓的适应症。
